Navigation Links
Harrington Discovery Institute's Dr. Jonathan Stamler earns AHA Distinguished Scientist Award
Date:11/21/2013

CLEVELAND, Nov. 21, 2013 /PRNewswire/ -- Jonathan Stamler, MD, Director of the Harrington Discovery Institute at University Hospitals (UH) Case Medical Center, has received the 2013 American Heart Association Distinguished Scientist Award at the association's annual conference in Dallas, TX.

(Photo: http://photos.prnewswire.com/prnh/20131121/CL22174)

This prestigious honor, the highest bestowed by the American Heart Association, recognizes individuals whose work has significantly advanced the understanding of cardiovascular disease and stroke. An internationally renowned physician-scientist, Dr. Stamler is recognized for the discovery of a universal mechanism by which the gas nitric oxide affects cellular function in biology.

Nitric oxide controls proteins in the body, helps transport oxygen to tissue and is critical to the physiological function of all organs and tissues, including the heart, nervous system and immune system. Dr. Stamler discovered a process, termed S-nitrosylation, by which nitric oxide attaches to proteins to control cellular function and his and related work has shown that aberrant signaling by S-nitrosylation may underlie the basis of numerous disease conditions, including heart disease, asthma, muscle disorders, and neurological diseases, as well as cancer, infection and aging. His findings anchor the development of new therapeutic approaches for patients with heart and other diseases.

Dr. Stamler is the Director, Harrington Discovery Institute at UH Case Medical Center and is the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at UH Case Medical Center and Case Western Reserve University School of Medicine. He also is Director, Institute for Transformative Molecular Medicine, and Professor of Medicine and Biochemistry at the School of Medicine.

Dr. Stamler has published more than 250 original articles and two books, has co-founded five companies, and serves on multiple editorial and scientific advisory boards. He is the author of more than 125 patents. He received his MD from Mount Sinai School of Medicine, completed his residency and fellowships in both cardiology and pulmonary medicine at Harvard Medical School and Brigham and Women's Hospital. Dr. Stamler joined the faculty at Harvard University before spending 16 years at Duke University. He joined Case Western Reserve and the UH Harrington Heart & Vascular Institute at UH Case Medical Center in 2010.

Dr. Stamler is currently conducting multiple National Institutes of Health- and Department of Defense-funded studies, to develop new drugs for treatment of heart, lung and blood disorders and complications of blood transfusion. He has also been recognized by several other prizes and awards, including being named among the "Top Innovators in America" by the Ewing Marion Kauffman Foundation.

In 2012, Dr. Stamler became the inaugural head of the Harrington Discovery Institute, a non-profit organization centered at UH Case Medical Center, which supports the efforts of physician-scientists to advance drug therapies. The HDI is part of a the Harrington Project for Discovery & Development, a $250 million national initiative dedicated to helping the nation's most promising physician-scientists advance breakthrough discoveries into medicines that benefit patients and society.

About University Hospitals
University Hospitals, the second largest employer in Northeast Ohio, serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians in 16 counties. At the core of our health system is University Hospitals Case Medical Center, one of only 18 hospitals in the country to have been named to U.S. News & World Report's most exclusive rankings list: the Best Hospitals 2013-14 Honor Roll. The primary affiliate of Case Western Reserve University School of Medicine, UH Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopaedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University. UH Case Medical Center is the 2012 recipient of the American Hospital Association – McKesson Quest for Quality Prize for its leadership and innovation in quality improvement and safety. For more information, go to www.uhhospitals.org


'/>"/>
SOURCE University Hospitals Case Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Douglas Harrington Speaks At The American Society For Preventive Cardiology Southeastern Conference 2013
2. Dr. Douglas Harrington Speaks At The American Society for Preventive Cardiology Southeastern Conference 2013
3. Douglas Harrington, MD Speaks At American Academy Of Physicians Assistants 2013 Conference In Washington, DC
4. Nominations Open for the Inaugural Harrington Prize for Innovation in Medicine
5. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
6. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
7. Biomarkers: Discovery Techniques and Applications - A Global Market Overview
8. Discovery Labs Reports Third Quarter 2013 Financial Results
9. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
10. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
11. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):